Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259128 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
A Phase 3 study, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT01259128: Completed Phase 3 study, sponsored by Serenity Pharmaceuticals.
NCT01259128 is a Phase 3 study that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 32 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01259128, a Phase 3 study, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
Primary Outcome
Mean serum sodium reported at baseline, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43 and Day 57.
Interventions
- DRUG SER120 Nasal Spray 500 ng/day
- DRUG SER120 nasal spray 750 ng/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
What the finished NCT01259128 record still lists
NCT01259128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which SER120 Nasal Spray 500 ng/day is the first listed.
NCT01259128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01259128 about?
NCT01259128 is a clinical study titled "Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia". The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
What is the current status of trial NCT01259128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2010-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01259128?
The interventions under investigation include: SER120 Nasal Spray 500 ng/day (DRUG), SER120 nasal spray 750 ng/day (DRUG).
Who is sponsoring clinical trial NCT01259128?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01259128's enrollment target sits among peer trials
32 1909th of 2000 higher than 87 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia